Fig. 6

Lenti-CGRP suppressed the high glucose-induced phosphorylation of ERK1/2 and p65. a Representative western blotting images of p-ERK1/2, ERK1/2, p-p65, p65 and GAPDH after 3 day glucose treatment. The data are shown as the mean ± SEM, *p < 0.05. b Western blotting images of p-ERK1/2 and ERK1/2 under 25 mM glucose conditions for 3 days. c Typical western blotting images of p-ERK1/2 and ERK1/2 in the lenti-CGRP group after treatment with the ERK1/2 inhibitor U0126 for 30 min under 50 mM glucose conditions for 3 days. The data are shown as the mean ± SEM, ^#p < 0.05. d The results of the annexin V/PI cell apoptosis assay under 50 mM glucose conditions for 5 days. The data are shown as the mean ± SEM. ^#p < 0.05 vs the 50 mM glucose-treated control group. e Representative images of the Matrigel assay upon U0126 treatment under 50 mM glucose conditions. The data are shown as the mean ± SEM. ^#p < 0.05 vs the 50 mM glucose-treated control group, *p < 0.05. Scale bar = 200 µm. f VEGF secretion under high glucose conditions upon U0126 treatment for 3 days, as determined by ELISA. The data are shown as the mean ± SEM. ^#p < 0.05 vs the 50 mM glucose-treated control group. g The mRNA expression of HIF-1α under high glucose conditions upon U0126 treatment for 3 days. The data are shown as the mean ± SEM, ^#p < 0.05 vs the 50 mM glucose-treated control group